12. Congenital myasthenic syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 6 / Drugs : 4 - (DrugBank : 3) / Drug target genes : 5 - Drug target pathways : 15
Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
3,4-diaminopyridine
Lahey Clinic
2001 - NCT00872950 United States
Ricardo Maselli
2017 - NCT03062631 United States
Vern C. Juel, M.D.
2012 - NCT01765140 United States
Albuterol
Mayo Clinic
2010 Phase 1 NCT01203592 United States
Amifampridine phosphate
Catalyst Pharmaceuticals, Inc.
2015 - NCT02189720 United States
ARGX-119
argenx
2024 Phase 1 NCT06436742 Canada;France;Italy;Spain;United Kingdom;United States
Lahey Clinic
2001 - NCT00872950 United States
Ricardo Maselli
2017 - NCT03062631 United States
Vern C. Juel, M.D.
2012 - NCT01765140 United States
Albuterol
Mayo Clinic
2010 Phase 1 NCT01203592 United States
Amifampridine phosphate
Catalyst Pharmaceuticals, Inc.
2015 - NCT02189720 United States
ARGX-119
argenx
2024 Phase 1 NCT06436742 Canada;France;Italy;Spain;United Kingdom;United States